Vincerx Pharma (NASDAQ:VINC) Releases Earnings Results, Hits Estimates

Vincerx Pharma (NASDAQ:VINC) issued its quarterly earnings results on Tuesday. The company reported ($0.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.17), reports.

Vincerx Pharma Trading Up 5.1 %

NASDAQ:VINC opened at $0.32 on Friday. The business’s fifty day moving average price is $0.52 and its 200 day moving average price is $0.64. The firm has a market capitalization of $10.57 million, a price-to-earnings ratio of -0.29 and a beta of 1.60. Vincerx Pharma has a 1-year low of $0.29 and a 1-year high of $9.37.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in shares of Vincerx Pharma by 29.9% during the 1st quarter. Vanguard Group Inc. now owns 666,995 shares of the company’s stock valued at $3,375,000 after acquiring an additional 153,575 shares in the last quarter. Marshall Wace LLP increased its holdings in Vincerx Pharma by 359.1% in the second quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock worth $266,000 after buying an additional 256,967 shares during the last quarter. Finally, Armistice Capital LLC bought a new position in Vincerx Pharma during the second quarter valued at approximately $1,610,000. 44.02% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Leerink Partners cut their price target on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.